Great Lakes Advisors LLC reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 18.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,015 shares of the medical equipment provider’s stock after selling 14,468 shares during the quarter. Great Lakes Advisors LLC’s holdings in Hologic were worth $4,764,000 as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of HOLX. Fieldpoint Private Securities LLC raised its stake in Hologic by 61.4% during the first quarter. Fieldpoint Private Securities LLC now owns 334 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 127 shares in the last quarter. Hudock Inc. raised its stake in Hologic by 1,825.0% during the first quarter. Hudock Inc. now owns 385 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 365 shares in the last quarter. FinTrust Capital Advisors LLC acquired a new position in Hologic during the first quarter worth $45,000. Quent Capital LLC acquired a new position in Hologic during the fourth quarter worth $51,000. Finally, Rosenberg Matthew Hamilton acquired a new position in Hologic during the first quarter worth $55,000. 92.70% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Hologic news, insider Jan Verstreken sold 6,500 shares of the firm’s stock in a transaction dated Tuesday, May 17th. The stock was sold at an average price of $78.80, for a total transaction of $512,200.00. Following the transaction, the insider now owns 64,191 shares in the company, valued at $5,058,250.80. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 1.54% of the company’s stock.
Hologic Price Performance
Hologic (NASDAQ:HOLX – Get Rating) last issued its earnings results on Wednesday, July 27th. The medical equipment provider reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.26. Hologic had a return on equity of 37.48% and a net margin of 28.93%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $896.71 million. During the same quarter last year, the business earned $1.33 earnings per share. The company’s revenue was down 14.2% compared to the same quarter last year. On average, equities analysts predict that Hologic, Inc. will post 5.82 earnings per share for the current year.
Analyst Ratings Changes
A number of analysts have recently weighed in on HOLX shares. Wells Fargo & Company lowered Hologic from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $90.00 to $75.00 in a research note on Monday, April 25th. Morgan Stanley lowered their target price on Hologic from $72.00 to $70.00 and set an “equal weight” rating for the company in a research note on Thursday, July 28th. UBS Group started coverage on Hologic in a research note on Wednesday, July 20th. They issued a “neutral” rating and a $73.00 target price for the company. BTIG Research lowered Hologic from a “buy” rating to a “neutral” rating in a research note on Monday, July 18th. Finally, Citigroup lowered their target price on Hologic from $78.00 to $75.00 in a research note on Thursday, April 28th. Seven research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Hologic presently has a consensus rating of “Hold” and a consensus price target of $76.71.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
- Get a free copy of the StockNews.com research report on Hologic (HOLX)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.